English
简体中文
Total: £ 56.28
Published Date: 2026-01-08 | Pages: 95 | Tables: 98 | Pharma & Healthcare
The global Injectable PrEP market was valued at US$ 308 million in 2025 and is anticipated to reach US$ 825 million by 2032, at a CAGR of 15.2% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Injectable PrEP competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Injectable PrEP refers to HIV pre-exposure prophylaxis administered via parenteral routes—typically intramuscular or subcutaneous injection—most often in long-acting formulations that create a sustained-release “depot” and maintain protective drug exposure for weeks to months before potential HIV exposure occurs. The core problem it is designed to solve is the real-world implementation gap of oral PrEP: daily or event-driven pill-taking can be difficult to sustain due to adherence burden, refill continuity, privacy constraints, and stigma associated with visible medication use, and missed doses or interruptions can translate into gaps in protection. By shifting prevention from frequent self-managed dosing to periodic clinic- or program-based administration, injectable PrEP aims to improve continuity of coverage, reduce day-to-day behavioral load, and integrate more naturally with testing, follow-up, and broader sexual health services. Historically, injectable PrEP emerged after oral PrEP established efficacy and guidelines, leveraging advances from long-acting HIV treatment technologies—such as micro-/nano-crystal suspensions, stable depot formulations, and aseptic fill-finish—before expanding through regulatory approvals and phased rollout across regions, with service delivery models (visit cadence, workforce training, cold chain, and retention-in-care) becoming a central determinant of real-world uptake. Upstream, injectable PrEP depends on both conventional pharmaceutical inputs and a component-intensive aseptic supply chain: APIs and key intermediates; chemical reagents, solvents, and catalysts; injection-grade excipients (stabilizers, surfactants, buffers, water for injection, and formulation aids as needed); and the packaging/device components required for sterile manufacturing and administration (injectable-grade glass vials or prefilled syringes, elastomer stoppers/plungers, seals, needles and safety injection devices, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish capacity, sterilization validation, temperature-controlled logistics, and compliant quality systems.In 2025, the global production capacity of injectable PrEP reached 150,000 doses, while total sales amounted to 115,700 doses. The average selling price was USD 2,660 per dose, and manufacturers’ gross margins ranged between 60% and 70%.
The North American market for Injectable PrEP is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Injectable PrEP is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
Major global manufacturers of Injectable PrEP include Gilead Sciences, ViiV Healthcare, Aurobindo, Cipla, Viatris, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Injectable PrEP market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Injectable PrEP. The Injectable PrEP market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Injectable PrEP market comprehensively. Regional market sizes by Type, by Application, by Dosing Interval, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Injectable PrEP manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Gilead Sciences
ViiV Healthcare
Aurobindo
Cipla
Viatris
Segment by Type
Cabotegravir
Lenacapavir
Other
Segment by Dosing Interval
Short-interval Injections
Monthly Injections
Quarterly Injections
Segment by Drug Properties
Original Drug
Generic Drug
by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Dosing Interval, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Injectable PrEP manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Injectable PrEP sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Injectable PrEP Market Overview
1.1 Product Definition
1.2 Injectable PrEP by Type
1.2.1 Global Injectable PrEP Market Value by Type: 2025 vs 2032
1.2.2 Cabotegravir
1.2.3 Lenacapavir
1.2.4 Other
1.3 Injectable PrEP by Dosing Interval
1.3.1 Global Injectable PrEP Market Value by Dosing Interval: 2025 vs 2032
1.3.2 Short-interval Injections
1.3.3 Monthly Injections
1.3.4 Quarterly Injections
1.4 Injectable PrEP by Drug Properties
1.4.1 Global Injectable PrEP Market Value by Drug Properties: 2025 vs 2032
1.4.2 Original Drug
1.4.3 Generic Drug
1.5 Injectable PrEP by Application
1.5.1 Global Injectable PrEP Market Value by Application: 2025 vs 2032
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Other
1.6 Global Injectable PrEP Market Size Estimates and Forecasts
1.6.1 Global Injectable PrEP Revenue 2021–2032
1.6.2 Global Injectable PrEP Sales 2021–2032
1.6.3 Global Injectable PrEP Market Average Price (2021–2032)
1.7 Assumptions and Limitations
2 Injectable PrEP Market Competition by Manufacturers
2.1 Global Injectable PrEP Sales Market Share by Manufacturers (2021–2026)
2.2 Global Injectable PrEP Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Injectable PrEP Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Injectable PrEP, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Injectable PrEP, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Injectable PrEP, Product Types and Applications
2.7 Global Key Manufacturers of Injectable PrEP, Date of Entry into the Industry
2.8 Global Injectable PrEP Market Competitive Situation and Trends
2.8.1 Global Injectable PrEP Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Injectable PrEP Players Market Share by Revenue
2.8.3 Global Injectable PrEP Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Injectable PrEP Market Scenario by Region
3.1 Global Injectable PrEP Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Injectable PrEP Sales by Region: 2021–2032
3.2.1 Global Injectable PrEP Sales by Region: 2021–2026
3.2.2 Global Injectable PrEP Sales by Region: 2027–2032
3.3 Global Injectable PrEP Revenue by Region: 2021–2032
3.3.1 Global Injectable PrEP Revenue by Region: 2021–2026
3.3.2 Global Injectable PrEP Revenue by Region: 2027–2032
3.4 North America Injectable PrEP Market Facts & Figures by Country
3.4.1 North America Injectable PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Injectable PrEP Sales by Country (2021–2032)
3.4.3 North America Injectable PrEP Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Injectable PrEP Market Facts & Figures by Country
3.5.1 Europe Injectable PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Injectable PrEP Sales by Country (2021–2032)
3.5.3 Europe Injectable PrEP Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Injectable PrEP Market Facts & Figures by Region
3.6.1 Asia Pacific Injectable PrEP Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Injectable PrEP Sales by Region (2021–2032)
3.6.3 Asia Pacific Injectable PrEP Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Injectable PrEP Market Facts & Figures by Country
3.7.1 Latin America Injectable PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Injectable PrEP Sales by Country (2021–2032)
3.7.3 Latin America Injectable PrEP Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Injectable PrEP Market Facts & Figures by Country
3.8.1 Middle East and Africa Injectable PrEP Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Injectable PrEP Sales by Country (2021–2032)
3.8.3 Middle East and Africa Injectable PrEP Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Injectable PrEP Sales by Type (2021–2032)
4.1.1 Global Injectable PrEP Sales by Type (2021–2026)
4.1.2 Global Injectable PrEP Sales by Type (2027–2032)
4.1.3 Global Injectable PrEP Sales Market Share by Type (2021–2032)
4.2 Global Injectable PrEP Revenue by Type (2021–2032)
4.2.1 Global Injectable PrEP Revenue by Type (2021–2026)
4.2.2 Global Injectable PrEP Revenue by Type (2027–2032)
4.2.3 Global Injectable PrEP Revenue Market Share by Type (2021–2032)
4.3 Global Injectable PrEP Price by Type (2021–2032)
5 Segment by Application
5.1 Global Injectable PrEP Sales by Application (2021–2032)
5.1.1 Global Injectable PrEP Sales by Application (2021–2026)
5.1.2 Global Injectable PrEP Sales by Application (2027–2032)
5.1.3 Global Injectable PrEP Sales Market Share by Application (2021–2032)
5.2 Global Injectable PrEP Revenue by Application (2021–2032)
5.2.1 Global Injectable PrEP Revenue by Application (2021–2026)
5.2.2 Global Injectable PrEP Revenue by Application (2027–2032)
5.2.3 Global Injectable PrEP Revenue Market Share by Application (2021–2032)
5.3 Global Injectable PrEP Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Gilead Sciences
6.1.1 Gilead Sciences Company Information
6.1.2 Gilead Sciences Description and Business Overview
6.1.3 Gilead Sciences Injectable PrEP Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Gilead Sciences Injectable PrEP Product Portfolio
6.1.5 Gilead Sciences Recent Developments/Updates
6.2 ViiV Healthcare
6.2.1 ViiV Healthcare Company Information
6.2.2 ViiV Healthcare Description and Business Overview
6.2.3 ViiV Healthcare Injectable PrEP Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 ViiV Healthcare Injectable PrEP Product Portfolio
6.2.5 ViiV Healthcare Recent Developments/Updates
6.3 Aurobindo
6.3.1 Aurobindo Company Information
6.3.2 Aurobindo Description and Business Overview
6.3.3 Aurobindo Injectable PrEP Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Aurobindo Injectable PrEP Product Portfolio
6.3.5 Aurobindo Recent Developments/Updates
6.4 Cipla
6.4.1 Cipla Company Information
6.4.2 Cipla Description and Business Overview
6.4.3 Cipla Injectable PrEP Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Cipla Injectable PrEP Product Portfolio
6.4.5 Cipla Recent Developments/Updates
6.5 Viatris
6.5.1 Viatris Company Information
6.5.2 Viatris Description and Business Overview
6.5.3 Viatris Injectable PrEP Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Viatris Injectable PrEP Product Portfolio
6.5.5 Viatris Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Injectable PrEP Industry Chain Analysis
7.2 Injectable PrEP Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Injectable PrEP Production Mode & Process Analysis
7.4 Injectable PrEP Sales and Marketing
7.4.1 Injectable PrEP Sales Channels
7.4.2 Injectable PrEP Distributors
7.5 Injectable PrEP Customer Analysis
8 Injectable PrEP Market Dynamics
8.1 Injectable PrEP Industry Trends
8.2 Injectable PrEP Market Drivers
8.3 Injectable PrEP Market Challenges
8.4 Injectable PrEP Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Injectable PrEP Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Injectable PrEP Market Value by Dosing Interval (US$ Million), 2025 vs 2032
Table 3. Global Injectable PrEP Market Value by Drug Properties (US$ Million), 2025 vs 2032
Table 4. Global Injectable PrEP Market Value by Application (US$ Million), 2025 vs 2032
Table 5. Global Injectable PrEP Market Competitive Situation by Manufacturers in 2025
Table 6. Global Injectable PrEP Sales (K Dose) of Key Manufacturers (2021–2026)
Table 7. Global Injectable PrEP Sales Market Share by Manufacturers (2021–2026)
Table 8. Global Injectable PrEP Revenue (US$ Million) by Manufacturers (2021–2026)
Table 9. Global Injectable PrEP Revenue Share by Manufacturers (2021–2026)
Table 10. Global Market Injectable PrEP Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 11. Global Key Players of Injectable PrEP, Industry Ranking, 2023 vs 2024 vs 2025
Table 12. Global Key Manufacturers of Injectable PrEP, Manufacturing Sites and Headquarters
Table 13. Global Key Manufacturers of Injectable PrEP, Product Types and Applications
Table 14. Global Key Manufacturers of Injectable PrEP, Date of Entry into the Industry
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Injectable PrEP Companies by Tier (Tier 1, Tier 2, Tier 3), based on Injectable PrEP Revenue, 2025
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 18. Global Injectable PrEP Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 19. Global Injectable PrEP Sales by Region (K Dose), 2021–2026
Table 20. Global Injectable PrEP Sales Market Share by Region (2021–2026)
Table 21. Global Injectable PrEP Sales by Region (K Dose), 2027–2032
Table 22. Global Injectable PrEP Sales Market Share by Region (2027–2032)
Table 23. Global Injectable PrEP Revenue by Region (US$ Million), 2021–2026
Table 24. Global Injectable PrEP Revenue Market Share by Region (2021–2026)
Table 25. Global Injectable PrEP Revenue by Region (US$ Million), 2027–2032
Table 26. Global Injectable PrEP Revenue Market Share by Region (2027–2032)
Table 27. North America Injectable PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 28. North America Injectable PrEP Sales by Country (K Dose), 2021–2026
Table 29. North America Injectable PrEP Sales by Country (K Dose), 2027–2032
Table 30. North America Injectable PrEP Revenue by Country (US$ Million), 2021–2026
Table 31. North America Injectable PrEP Revenue by Country (US$ Million), 2027–2032
Table 32. Europe Injectable PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 33. Europe Injectable PrEP Sales by Country (K Dose), 2021–2026
Table 34. Europe Injectable PrEP Sales by Country (K Dose), 2027–2032
Table 35. Europe Injectable PrEP Revenue by Country (US$ Million), 2021–2026
Table 36. Europe Injectable PrEP Revenue by Country (US$ Million), 2027–2032
Table 37. Asia Pacific Injectable PrEP Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 38. Asia Pacific Injectable PrEP Sales by Region (K Dose), 2021–2026
Table 39. Asia Pacific Injectable PrEP Sales by Region (K Dose), 2027–2032
Table 40. Asia Pacific Injectable PrEP Revenue by Region (US$ Million), 2021–2026
Table 41. Asia Pacific Injectable PrEP Revenue by Region (US$ Million), 2027–2032
Table 42. Latin America Injectable PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 43. Latin America Injectable PrEP Sales by Country (K Dose), 2021–2026
Table 44. Latin America Injectable PrEP Sales by Country (K Dose), 2027–2032
Table 45. Latin America Injectable PrEP Revenue by Country (US$ Million), 2021–2026
Table 46. Latin America Injectable PrEP Revenue by Country (US$ Million), 2027–2032
Table 47. Middle East and Africa Injectable PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 48. Middle East and Africa Injectable PrEP Sales by Country (K Dose), 2021–2026
Table 49. Middle East and Africa Injectable PrEP Sales by Country (K Dose), 2027–2032
Table 50. Middle East and Africa Injectable PrEP Revenue by Country (US$ Million), 2021–2026
Table 51. Middle East and Africa Injectable PrEP Revenue by Country (US$ Million), 2027–2032
Table 52. Global Injectable PrEP Sales (K Dose) by Type (2021–2026)
Table 53. Global Injectable PrEP Sales (K Dose) by Type (2027–2032)
Table 54. Global Injectable PrEP Sales Market Share by Type (2021–2026)
Table 55. Global Injectable PrEP Sales Market Share by Type (2027–2032)
Table 56. Global Injectable PrEP Revenue (US$ Million) by Type (2021–2026)
Table 57. Global Injectable PrEP Revenue (US$ Million) by Type (2027–2032)
Table 58. Global Injectable PrEP Revenue Market Share by Type (2021–2026)
Table 59. Global Injectable PrEP Revenue Market Share by Type (2027–2032)
Table 60. Global Injectable PrEP Price (US$/Dose) by Type (2021–2026)
Table 61. Global Injectable PrEP Price (US$/Dose) by Type (2027–2032)
Table 62. Global Injectable PrEP Sales (K Dose) by Application (2021–2026)
Table 63. Global Injectable PrEP Sales (K Dose) by Application (2027–2032)
Table 64. Global Injectable PrEP Sales Market Share by Application (2021–2026)
Table 65. Global Injectable PrEP Sales Market Share by Application (2027–2032)
Table 66. Global Injectable PrEP Revenue (US$ Million) by Application (2021–2026)
Table 67. Global Injectable PrEP Revenue (US$ Million) by Application (2027–2032)
Table 68. Global Injectable PrEP Revenue Market Share by Application (2021–2026)
Table 69. Global Injectable PrEP Revenue Market Share by Application (2027–2032)
Table 70. Global Injectable PrEP Price (US$/Dose) by Application (2021–2026)
Table 71. Global Injectable PrEP Price (US$/Dose) by Application (2027–2032)
Table 72. Gilead Sciences Company Information
Table 73. Gilead Sciences Description and Business Overview
Table 74. Gilead Sciences Injectable PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 75. Gilead Sciences Injectable PrEP Product
Table 76. Gilead Sciences Recent Developments/Updates
Table 77. ViiV Healthcare Company Information
Table 78. ViiV Healthcare Description and Business Overview
Table 79. ViiV Healthcare Injectable PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 80. ViiV Healthcare Injectable PrEP Product
Table 81. ViiV Healthcare Recent Developments/Updates
Table 82. Aurobindo Company Information
Table 83. Aurobindo Description and Business Overview
Table 84. Aurobindo Injectable PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 85. Aurobindo Injectable PrEP Product
Table 86. Aurobindo Recent Developments/Updates
Table 87. Cipla Company Information
Table 88. Cipla Description and Business Overview
Table 89. Cipla Injectable PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 90. Cipla Injectable PrEP Product
Table 91. Cipla Recent Developments/Updates
Table 92. Viatris Company Information
Table 93. Viatris Description and Business Overview
Table 94. Viatris Injectable PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 95. Viatris Injectable PrEP Product
Table 96. Viatris Recent Developments/Updates
Table 97. Key Raw Materials Lists
Table 98. Raw Materials Key Suppliers Lists
Table 99. Injectable PrEP Distributors List
Table 100. Injectable PrEP Customers List
Table 101. Injectable PrEP Market Trends
Table 102. Injectable PrEP Market Drivers
Table 103. Injectable PrEP Market Challenges
Table 104. Injectable PrEP Market Restraints
Table 105. Research Programs/Design for This Report
Table 106. Key Data Information from Secondary Sources
Table 107. Key Data Information from Primary Sources
Table 108. Authors List of This Report
List of Figures
Figure 1. Product Picture of Injectable PrEP
Figure 2. Global Injectable PrEP Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Injectable PrEP Market Share by Type: 2025 & 2032
Figure 4. Cabotegravir Product Picture
Figure 5. Lenacapavir Product Picture
Figure 6. Other Product Picture
Figure 7. Global Injectable PrEP Market Value by Dosing Interval (US$ Million), 2021–2032
Figure 8. Global Injectable PrEP Market Share by Dosing Interval: 2025 vs 2032
Figure 9. Short-interval Injections Product Picture
Figure 10. Monthly Injections Product Picture
Figure 11. Quarterly Injections Product Picture
Figure 12. Global Injectable PrEP Market Value by Drug Properties (US$ Million), 2021–2032
Figure 13. Global Injectable PrEP Market Share by Drug Properties: 2025 vs 2032
Figure 14. Original Drug Product Picture
Figure 15. Generic Drug Product Picture
Figure 16. Global Injectable PrEP Market Value by Application (US$ Million), 2021–2032
Figure 17. Global Injectable PrEP Market Share by Application: 2025 & 2032
Figure 18. Hospital
Figure 19. Clinic
Figure 20. Other
Figure 21. Global Injectable PrEP Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 22. Global Injectable PrEP Market Size (US$ Million), 2021–2032
Figure 23. Global Injectable PrEP Sales (K Dose), 2021–2032
Figure 24. Global Injectable PrEP Average Price (US$/Dose), 2021–2032
Figure 25. Injectable PrEP Report Years Considered
Figure 26. Injectable PrEP Sales Share by Manufacturers in 2025
Figure 27. Global Injectable PrEP Revenue Share by Manufacturers in 2025
Figure 28. Top 5 and Top 10 Global Injectable PrEP Players: Market Share by Revenue in Injectable PrEP in 2025
Figure 29. Injectable PrEP Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 30. Global Injectable PrEP Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 31. North America Injectable PrEP Sales Market Share by Country (2021–2032)
Figure 32. North America Injectable PrEP Revenue Market Share by Country (2021–2032)
Figure 33. United States Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Canada Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Europe Injectable PrEP Sales Market Share by Country (2021–2032)
Figure 36. Europe Injectable PrEP Revenue Market Share by Country (2021–2032)
Figure 37. Germany Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. France Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. U.K. Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Italy Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Russia Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Asia Pacific Injectable PrEP Sales Market Share by Region (2021–2032)
Figure 43. Asia Pacific Injectable PrEP Revenue Market Share by Region (2021–2032)
Figure 44. China Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Japan Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. South Korea Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. India Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Australia Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. China Taiwan Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Southeast Asia Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Latin America Injectable PrEP Sales Market Share by Country (2021–2032)
Figure 52. Latin America Injectable PrEP Revenue Market Share by Country (2021–2032)
Figure 53. Mexico Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. Brazil Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Argentina Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Colombia Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Middle East and Africa Injectable PrEP Sales Market Share by Country (2021–2032)
Figure 58. Middle East and Africa Injectable PrEP Revenue Market Share by Country (2021–2032)
Figure 59. Turkey Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 60. Saudi Arabia Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. UAE Injectable PrEP Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Global Sales Market Share of Injectable PrEP by Type (2021–2032)
Figure 63. Global Revenue Market Share of Injectable PrEP by Type (2021–2032)
Figure 64. Global Injectable PrEP Price (US$/Dose) by Type (2021–2032)
Figure 65. Global Sales Market Share of Injectable PrEP by Application (2021–2032)
Figure 66. Global Revenue Market Share of Injectable PrEP by Application (2021–2032)
Figure 67. Global Injectable PrEP Price (US$/Dose) by Application (2021–2032)
Figure 68. Injectable PrEP Value Chain
Figure 69. Channels of Distribution (Direct Vs Distribution)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
